At the forefront of oncology
Ryvu Therapeutics discovers and develops small molecule therapies that address high value emerging targets in oncology.
Our pipeline is built from internally-discovered candidates which make use of diverse therapeutic mechanisms, including programs directed at targets in the areas of transcriptional regulation, synthetic lethality and immuno-oncology.
INNOVATING CANCER TREATMENT
Clinical & preclinical programs
Ryvu is developing novel therapies to address high-value emerging targets in oncology.
PRECISION ON THE TARGET
Novel Multi-Target Discovery
Ryvu is pioneering a multi-target discovery approach to develop innovative therapies that address complex oncogenic pathways. By integrating advanced screening technologies and deep biological insights, we aim to create highly effective treatments for cancer.
PARTNERING TO ADVANCE CANCER THERAPIES
Platform Collaborations
Beyond publicly disclosed programs, Ryvu is working on candidates that address novel targets in the areas of synthetic lethality, immuno-oncology and immunometabolism to generate new therapeutics with first-in-class or best-in-class potential.
Publications
- pdf file
RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: preliminary results from two ongoing studies.
Download - pdf file
Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.
Download - pdf file
CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.
Download
- pdf file
Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment
Download - pdf file
Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies
Download